Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report
Frontiers in Pediatrics · 17.06.2026 · 14
DOI: 10.3389/fped.2026.1855822 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 17.06.2026. Verfasst von Antonella Mosca und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology and Liver Transplant Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Transplant-associated allergy represents a clinically relevant phenomenon described after hematopoietic stem cell transplantation and, particularly in pediatric patients, after solid organ transplantation. Liver transplant (LT) in the pediatric population is associated with de novo IgE-mediated allergy, including asthma, atopic dermatitis, and severe food allergies. De novo post-transplant food allergy (dnPTFA) is a condition with multiple risk factors involved, including young recipient age, female sex, personal or donor history of atopy, calcineurin inhibitors, and Epstein–Barr virus infection. These factors likely converge to promote post-transplant immune dysregulation through both passive and active mechanisms driven by calcineurin inhibitor (CNI)-induced Th2 skewing and viral immune modulation. This paper presents a narrative review of dnPTFA and a clinical case of a 15-year-old boy who underwent LT at 28 days of age due to neonatal acute liver failure. The patient subsequently developed severe asthma and multiple dnPTFAs with recurrent anaphylaxis, despite immunosuppression being maintained at low target levels throughout post-transplant follow-up due to normal graft function. Because of persistent life-threatening reactions, allergic asthma, and marked food selectivity compromising growth, off-label treatment with omalizumab was initiated at 10 years of age. Following treatment with omalizumab, the patient achieved excellent asthma control, discontinued background therapy, and resumed a less restricted diet. Liver graft function has remained stable, with no graft-related adverse events over more than 5 years of follow-up, supporting the long-term safety and effectiveness of this approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology and Liver Transplant Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Division of Allergy, University Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Zitieren
APA
Mosca, A., Ficari, A., Basso, M. S., Mazzuca, C., Liccardo, D., Fiocchi, A., Pietrobattista, A., & Fierro, V. (2026). Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1855822
Vancouver
Mosca A, Ficari A, Basso MS, Mazzuca C, Liccardo D, Fiocchi A, et al. Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1855822
BibTeX
@article{Mosca2026,
author = {Mosca, Antonella and Ficari, Andrea and Basso, Maria Sole and Mazzuca, Carmen and Liccardo, Daniela and Fiocchi, Alessandro and Pietrobattista, Andrea and Fierro, Vincenzo},
title = {Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1855822}
}
EUVIMED